jnj-87189401
mAbexperimentalBi-specific
Clinical trial activity
1 trials · 0 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2023 (NCT06095089)
Timeline
No events for the selected filters.
Mechanism of action
CD28 inhibitor
- Glutamate carboxypeptidase IIINHIBITOR
FOLH1 inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06095089 | Phase 1 | Nov 1, 2023 | — |
Showing 1 of 1 trials
Page 1 / 1